Medpace/$MEDP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Medpace
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Ticker
$MEDP
Sector
Primary listing
Employees
6,000
Headquarters
Website
Medpace Metrics
BasicAdvanced
$15B
40.63
$13.46
1.44
-
Price and volume
Market cap
$15B
Beta
1.44
52-week high
$554.14
52-week low
$250.05
Average daily volume
327K
Financial strength
Current ratio
0.427
Quick ratio
0.348
Long term debt to equity
72.495
Total debt to equity
98.535
Profitability
EBITDA (TTM)
506.477
Gross margin (TTM)
68.51%
Net profit margin (TTM)
18.74%
Operating margin (TTM)
21.40%
Effective tax rate (TTM)
15.56%
Revenue per employee (TTM)
$370,000
Management effectiveness
Return on assets (TTM)
17.09%
Return on equity (TTM)
89.38%
Valuation
Price to earnings (TTM)
40.628
Price to revenue (TTM)
7.409
Price to book
88.88
Price to tangible book (TTM)
-29.24
Price to free cash flow (TTM)
28.518
Free cash flow yield (TTM)
3.51%
Free cash flow per share (TTM)
19.172
Growth
Revenue change (TTM)
9.94%
Earnings per share change (TTM)
26.42%
3-year revenue growth (CAGR)
20.16%
3-year earnings per share growth (CAGR)
32.76%
What the Analysts think about Medpace
Analyst ratings (Buy, Hold, Sell) for Medpace stock.
Bulls say / Bears say
Medpace’s Q2 2025 revenue of $603 million and EPS of $3.10 topped consensus forecasts (by ~12% and ~4%, respectively), fueling a record single-day stock surge of over 50% and underscoring strong investor confidence in its operational performance (Barron's).
The company raised its full-year 2025 EPS guidance to a range of $13.76–$14.53 from $12.26–$13.04, reflecting management’s confidence in sustaining robust revenue momentum and margin expansion (Barron's).
Medpace notably increased its full-year revenue outlook following Q2 due to improved funding conditions, fewer cancellations, and quicker client decisions, signaling stabilizing demand for its CRO services amid sector headwinds (Reuters).
TipRanks highlighted challenges from Medpace’s Q2 earnings call, including a 1.8% year-over-year decrease in backlog as of June 30, 2025, lower win rates, and rising reimbursable costs, raising questions about the sustainability of its growth trajectory (TipRanks).
Cash and cash equivalents plunged to just $46.3 million as of June 30, 2025, largely due to $518.5 million of share repurchases in Q2, potentially constraining liquidity for future operations and strategic investments (RTTNews).
Medpace’s Q1 2025 net new business awards of $500 million missed both William Blair and FactSet consensus estimates for the fifth consecutive quarter, underscoring persistent weakness in bookings and client demand (Investor's Business Daily).
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
Medpace Financial Performance
Revenues and expenses
Medpace Earnings Performance
Company profitability
Medpace News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Medpace stock?
Medpace (MEDP) has a market cap of $15B as of October 23, 2025.
What is the P/E ratio for Medpace stock?
The price to earnings (P/E) ratio for Medpace (MEDP) stock is 40.63 as of October 23, 2025.
Does Medpace stock pay dividends?
No, Medpace (MEDP) stock does not pay dividends to its shareholders as of October 23, 2025.
When is the next Medpace dividend payment date?
Medpace (MEDP) stock does not pay dividends to its shareholders.
What is the beta indicator for Medpace?
Medpace (MEDP) has a beta rating of 1.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.